Amanote Research
Register
Sign In
Systemic Exposure, Tolerability, and Efficacy of Pimecrolimus Cream 1% in Atopic Dermatitis Patients
Archives of Disease in Childhood
- United Kingdom
doi 10.1136/adc.88.11.969
Full Text
Open PDF
Abstract
Available in
full text
Categories
Child Health
Pediatrics
Perinatology
Date
November 1, 2003
Authors
B R Allen
Publisher
BMJ
Related search
Sustained Efficacy and Safety of Pimecrolimus Cream 1% When Used Long-Term (Up to 26 Weeks) to Treat Children With Atopic Dermatitis
Pediatrics
Child Health
Pediatrics
Perinatology
Ruxolitinib Cream Suppresses Th2 Inflammation in Adult Patients With Atopic Dermatitis
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Long-Term Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% in Infants Does Not Interfere With the Development of Protective Antibodies After Vaccination
Pediatrics
Child Health
Pediatrics
Perinatology
PAC‐14028 Cream for Atopic Dermatitis
British Journal of Dermatology
Dermatology
Medicine
998 Ruxolitinib Cream Significantly Modulates Inflammatory Profiles of Atopic Dermatitis Patients
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
The Safety and Efficacy of Pimecrolimus, 1%, Cream for the Treatment of Netherton Syndrome
Archives of Dermatology
Novel Therapeutic Approach With PAC ‐14028 Cream, a TRPV 1 Antagonist, for Patients With Mild‐to‐moderate Atopic Dermatitis
British Journal of Dermatology
Dermatology
Medicine
Management of Atopic Dermatitis: Safety and Efficacy of Phototherapy
Clinical, Cosmetic and Investigational Dermatology
Dermatology
605 Efficacy and Safety of Dupilumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
